Expression of CD40 and growth-inhibitory activity of CD40 ligand in colon cancer ex vivo

Cellular Immunology

Volumn 253, Issue 1-2, 2008, Pages 102-109

  Wu, Yugang ^a   Wang, Liang ^b   He, Xiaozhou ^a   Xu, Haiyan ^a   Zhou, Lechang ^c   Zhao, Fang ^c   Zhang, Yanyun ^c  

^a THE THIRD AFFILIATED HOSPITAL OF SOOCHOW UNIVERSITY   (China)

^b SOOCHOW UNIVERSITY   (China)

^c SHANGHAI UNIVERSITY OF MEDICINE AND HEALTH SCIENCES   (China)

Author keywords

CD40; CD40 ligand; Colon cancer; IFN ; Proliferation

Indexed keywords

CD40 ANTIGEN; CD40 LIGAND; GAMMA INTERFERON;

ADULT; APOPTOSIS; ARTICLE; COLON CANCER; CONTROLLED STUDY; EX VIVO STUDY; FEMALE; FLOW CYTOMETRY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; MALE; PRIORITY JOURNAL; PROTEIN EXPRESSION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANTIGENS, CD40; APOPTOSIS; CARCINOMA, RENAL CELL; CD40 LIGAND; CELL LINE, TUMOR; CELL PROLIFERATION; COLONIC NEOPLASMS; FEMALE; HUMANS; MALE; MIDDLE AGED; RECOMBINANT PROTEINS;

EID: 51649083689     PISSN: 00088749     EISSN: 10902163     Source Type: Journal    
DOI: 10.1016/j.cellimm.2008.05.005     Document Type: Article

References (37)

1. Rougier P., Andre T., Panis Y., Colin P., Stremsdoerfer N., and Laurent-Puig P. Colon cancer. Gastroenterol. Clin. Biol. 30 (2006) 2S24-2S29
2. McCormick D., Kibbe P.J., and Morgan S.W. Colon cancer: prevention, diagnosis, treatment. Gastroenterol. Nurs. 25 (2002) 204-211
3. Colquhoun P.H., and Wexner S.D. Surgical management of colon cancer. Curr. Gastroenterol. Rep. 4 (2002) 414-419
4. Kalyn R. Overview of targeted therapies in Oncology. J. Oncol. Pharm. Pract. 13 (2007) 199-205
5. Herbst R.S. Role of novel targeted therapies in the clinic. Br. J. Cancer 92 (2005) S21-S27
6. Walcher P., Mayr U.B., Azimpour-Tabrizi C., Eko F.O., Jechlinger W., Mayrhofer P., et al. Antigen discovery and delivery of subunit vaccines by nonliving bacterial ghost vectors. Expert Rev. Vaccines 3 (2004) 681-691
7. Ryschich E., Märten A., Schmidt E., Linnebacher M., Wentzensen N., Eisold S., et al. Activating anti-CD40 antibodies induce tumour invasion by cytotoxic T-lymphocytes and inhibition of tumour growth in experimental liver cancer. Eur. J. Cancer 42 (2006) 981-987
8. Lum H.D., Buhtoiarov I.N., Schmidt B.E., Berke G., Paulnock D.M., Sondel P.M., et al. In vivo CD40 ligation can induce T-cell-independent antitumor effects that involve macrophages. J. Leukoc. Biol. 79 (2006) 1181-1192
9. Van kooten C., and Banchereau J. CD40-CD40 ligand. J. Leukoc. Biol. 67 (2000) 2-7
10. Schönbeck U., and Libby P. The CD40/CD154 receptor/ligand dyad. Cell. Mol. Life Sci. 58 (2001) 4-43
11. Bishop G.A., and Hostager B.S. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev. 14 (2003) 297-309
12. Tong A.W., and Stone M.J. Prospects for CD40-directed experimental therapy of human cancer. Cancer Gene Ther. 10 (2003) 1-13
13. Xu Y., and Song G. The role of CD40-CD154 interaction in cell immunoregulation. J. Biomed. Sci. 11 (2004) 426-438
14. Schönbeck U., Mach F., and Libby P. CD154 (CD40 ligand). Int. J. Biochem. Cell Biol. 32 (2000) 687-693
15. Tong A.W., Papayoti M.H., Netto G., Armstrong D.T., Ordonez G., Lawson J.M., et al. Growth-inhibitory effects of CD40 ligand (CD154) and its endogenous expression in human breast cancer. Clin. Cancer Res. 7 (2001) 691-703
16. Sabel M.S., Yamada M., Kawaguchi Y., Chen F.A., Takita H., and Bankert R.B. CD40 expression on human lung cancer correlates with metastatic spread. Cancer Immunol. Immunother. 49 (2000) 101-108
17. Ottaiano A., De Chiara A., Perrone F., Botti G., Fazioli F., De Rosa V., et al. Prognostic value of CD40 in adult soft tissue sarcomas. Clin. Cancer Res. 10 (2004) 2824-2831
18. Gallagher N.J., Eliopoulos A.G., Agathangelo A., Oates J., Crocker J., and Young L.S. CD40 activation in epithelial ovarian carcinoma cells modulates growth, apoptosis, and cytokine secretion. Mol. Pathol. 55 (2002) 110-120
19. Voorzanger-Rousselot N., and Blay J.Y. Coexpression of CD40 and CD40L on B lymphoma and carcinoma cells: an autocrine anti-apoptotic role. Leuk. Lymphoma 45 (2004) 1239-1245
20. Thorburn A. Tumor necrosis factor-related apoptosis-inducing ligand (TRAIL) pathway signaling. J. Thorac. Oncol. 2 (2007) 461-465
21. Abe K., Kurakin A., Mohseni-Maybodi M., Kay B., and Khosravi-Far R. The complexity of TNF-related apoptosis-inducing ligand. Ann. NY Acad. Sci. 926 (2000) 52-63
22. Vonderheide R.H. Prospect of targeting the CD40 pathway for cancer therapy. Clin. Cancer Res. 13 (2007) 1083-1088
23. Francisco J.A., Donaldson K.L., Chace D., Siegall C.B., and Wahl A.F. Agonistic properties and in vivo antitumor activity of the anti-CD40 antibody SGN-14. Cancer Res. 60 (2000) 3225-3231
24. Batrla R., Linnebacher M., Rudy W., Stumm S., Wallwiener D., and Gückel B. CD40-expressing carcinoma cells induce down-regulation of CD40 ligand (CD154) and impair T-cell functions. Cancer Res. 62 (2002) 2052-2057
25. Quezada S.A., Jarvinen L.Z., Lind E.F., and Noelle R.J. CD40/CD154 interactions at the interface of tolerance and immunity. Annu. Rev. Immunol. 22 (2004) 307-328
26. Bishop G.A., and Hostager B.S. The CD40-CD154 interaction in B cell-T cell liaisons. Cytokine Growth Factor Rev. 14 (2003) 297-309
27. Dadgostar H., Zarnegar B., Hoffmann A., Qin X.F., Truong U., Rao G., Baltimore D., et al. Cooperation of multiple signaling pathways in CD40-regulated gene expression in B lymphocytes. Proc. Natl. Acad. Sci. USA 99 (2002) 1497-1502
28. Zarnegar B., He J.Q., Oganesyan G., Hoffmann A., Baltimore D., and Cheng G. Unique CD40-mediated biological program in B cell activation requires both type 1 and type 2 NF-kappaB activation pathways. Proc. Natl. Acad. Sci. USA 101 (2004) 8108-8113
29. Mineva N.D., Rothstein T.L., Meyers J.A., Lerner A., and Sonenshein G.E. CD40 ligand-mediated activation of the de novo RelB NF-kappaB synthesis pathway in transformed B cells promotes rescue from apoptosis. J. Biol. Chem. 282 (2007) 17475-17485
30. Eliopoulos A.G., Dawson C.W., Mosialos G., Floettmann J.E., Rowe M., Armitage R.J., et al. CD40-induced growth inhibition in epithelial cells is mimicked by Epstein-Barr Virus-encoded LMP1: involvement of TRAF3 as a common mediator. Oncogene 13 (1996) 2243-2254
31. Eliopoulos A.G., and Young L.S. The role of the CD40 pathway in the pathogenesis and treatment of cancer. Curr. Opin. Pharmacol. 4 (2004) 360-367
32. Eliopoulos A.G., Davies C., Knox P.G., Gallagher N.J., Afford S.C., Adams D.H., et al. CD40 induces apoptosis in carcinoma cells through activation of cytotoxic ligands of the tumor necrosis factor superfamily. Mol. Cell. Biol. 20 (2000) 5503-5515
33. Chin Y.E., Kitagawa M., Su W.C., You Z.H., Iwamoto Y., and Fu X.Y. Cell growth arrest and induction of cyclin-dependent kinase inhibitor p21 WAF1/CIP1 mediated by STAT1. Science 272 (1996) 719-722
34. Gooch J.L., Herrera R.E., and Yee D. The role of p21 in interferon gamma-mediated growth inhibition of human breast cancer cells. Cell Growth Differ. 11 (2000) 335-342
35. Chen B., He L., Savell V.H., Jenkins J.J., and Parham D.M. Inhibition of the interferon-gamma/signal transducers and activators of transcription (STAT) pathway by hypermethylation at a STAT-binding site in the p21WAF1 promoter region. Cancer Res. 60 (2000) 3290-3298
36. Melichar B., Patenia R., Gallardo S., Melicharová K., Hu W., and Freedman R.S. Expression of CD40 and growth-inhibitory activity of CD40 ligand in ovarian cancer cell lines. Gynecol. Oncol. 104 (2007) 707-713
37. Suk K., Kim Y.H., Chang I., Kim J.Y., Choi Y.H., Lee K.Y., et al. IFNalpha sensitizes ME-180 human cervical cancer cells to TNFalpha-induced apoptosis by inhibiting cytoprotective NF-kappaB activation. FEBS Lett. 20 (2001) 66-70